John C. Byrd - Concepedia

Author

John C. Byrd

The Ohio State University

Also Known As

Byrd, John, Cheson, Bruce D., Dunson, David, J BYRD, J C Byrd, J. C. Byrd, J.C. Byrd, JOHN BYRD, John Byrd, John C Byrd

201

Publications

17.1K

Citations

H-Index

Concepts

All Affiliations

The Ohio State University The University of Texas MD Anderson Cancer Center Sarah Cannon Cornell University University of California San Diego

About

John C. Byrd is an author at The Ohio State University specializing in medicine, immunology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	35	2.1K
2	Natural Sciences	4	4	168
3	Health Sciences	3	3	348
4	Biochemistry	3	3	142
5	Public Health	1	1	42

John C. Byrd

116

Publications

16.3K

Citations

H-Index

Page 1

	Year	Citations
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia John C. Byrd, Richard R. Furman, Steven Coutré, New England Journal of Medicine	2013	2.2K
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia John C. Byrd, Jennifer R. Brown, Susan O’Brien, New England Journal of Medicine	2014	1.6K
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study Michael J. Keating, Ian W. Flinn, Vinay Jain, Blood	2002	946
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, New England Journal of Medicine	2018	927
ZAP-70 Compared with Immunoglobulin Heavy-Chain Gene Mutation Status as a Predictor of Disease Progression in Chronic Lymphocytic Leukemia Laura Z. Rassenti, Lang Huynh, Tracy L. Toy, New England Journal of Medicine	2004	905
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia Jennifer R. Brown, John C. Byrd, Steven Coutré, Blood	2014	583
Genetic heterogeneity of diffuse large B-cell lymphoma Jenny Zhang, Vladimir Grubor, Cassandra Love, Proceedings of the National Academy of Sciences	2013	530
Rituximab Using A Thrice Weekly Dosing Schedule in B-Cell Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Demonstrates Clinical Activity and Acceptable Toxicity John C. Byrd, Timothy J. Murphy, Robin Howard, Journal of Clinical Oncology	2001	511
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions Gerard Lozanski, Nyla A. Heerema, Ian W. Flinn, Blood	2004	403
The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction John C. Byrd, Shinichi Kitada, Ian W. Flinn, Blood	2002	363

Page 1